Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT07102901
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Metastatic Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR2554 Tablets — DRUG
    Oral SHR2554 tablets.
  • SHR-A1811 Injection — DRUG
    SHR-A1811 for injection.
  • SHR-A1904 Injection — DRUG
    SHR-A1904 for injection.
  • SHR-1701 Injection — DRUG
    SHR-1701 injection

Study Details

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Key Dates

First listed
Aug 5, 2025
Start date
Sep 5, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
351 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group A
  • Experimental: Treatment group B
  • Experimental: Treatment group C
  • Experimental: Treatment group D

Primary Outcome Measure

Incidence and severity of adverse events (AEs). [ Time Frame: Up to approximately 2 years. ]

Central Contacts

Related Studies